
Medtronic plc.: shareholders and insiders
Price
$100.72
November 18, 2026Market cap $129B
What Ploutos Investor adds for Medtronic
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from FY2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 4, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$15M
5 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan41%
- The rest59%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $12M by 4 people
- 2025: no buys, sold $3.1M by 1 person
- 2026: no buys, sold $12M by 4 people
- Nov 2, 2026Michael MarinaroPresidentKind
- Oct 15, 2026Kevin E LoftonDirectorKind
- Oct 15, 2026Michael MarinaroEVP, Pres MedSurg and AmericasKind10b5-1
- Oct 15, 2026Geoffrey MarthaChairman and CEOKind10b5-1
- Sep 16, 2026Harry Skip KiilEVP & President CardiovascularKind
- Sep 15, 2026Denise L. BlomquistChief Accounting OfficerKind
- Aug 20, 2026Michael MarinaroEVP, Pres MedSurg and AmericasKind
- Aug 3, 2026Denise L. BlomquistChief Accounting OfficerKind
- Aug 3, 2026Matthew R. WalterSVP, Chief HR OfficerKind
- Aug 3, 2026Kweli ThompsonEVP & President, NeuroscienceKind
- Aug 3, 2026Michelle QuinnEVP, GC and SecretaryKind
- Aug 3, 2026Thierry PietonEVP & Chief Financial OfficerKind
- Aug 3, 2026Michael MarinaroEVP, Pres MedSurg and AmericasKind
- Aug 3, 2026Michael MarinaroEVP, Pres MedSurg and AmericasKind
- Aug 3, 2026Harry Skip KiilEVP & President CardiovascularKind
- Aug 3, 2026Geoffrey MarthaChairman and CEOKind
- Jul 31, 2026Denise L. BlomquistChief Accounting OfficerKind
- Jul 31, 2026Matthew R. WalterSVP, Chief HR OfficerKind
- Jul 31, 2026Kweli ThompsonEVP & President, NeuroscienceKind
- Jul 31, 2026Michael MarinaroEVP, Pres MedSurg and AmericasKind
- Jul 31, 2026Harry Skip KiilEVP & President CardiovascularKind
- Jul 31, 2026Geoffrey MarthaChairman and CEOKind
- Jul 28, 2026Michelle QuinnEVP, GC and SecretaryKind
- Jul 8, 2026Matthew R. WalterSVP, Chief HR OfficerKind10b5-1
- Jun 8, 2026Harry Skip KiilEVP & President CardiovascularKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | Michael MarinaroPresident | 6,547 | – | – | Form 4 | |
| Oct 15, 2026 | Kevin E LoftonDirector | 182 | – | – | Form 4 | |
| Oct 15, 2026 | Michael MarinaroEVP, Pres MedSurg and Americas | 10b5-1 | 10.4K | $96.00 | $1.0M | Form 4 |
| Oct 15, 2026 | Geoffrey MarthaChairman and CEO | 10b5-1 | 50.0K | $95.00 | $4.8M | Form 4 |
| Sep 16, 2026 | Harry Skip KiilEVP & President Cardiovascular | 1,483 | $93.65 | $138.9K | Form 4 | |
| Sep 15, 2026 | Denise L. BlomquistChief Accounting Officer | 600 | – | – | Form 4 | |
| Aug 20, 2026 | Michael MarinaroEVP, Pres MedSurg and Americas | 1,084 | $92.30 | $100.1K | Form 4 | |
| Aug 3, 2026 | Denise L. BlomquistChief Accounting Officer | 2,337 | – | – | Form 4 | |
| Aug 3, 2026 | Matthew R. WalterSVP, Chief HR Officer | 5,769 | – | – | Form 4 | |
| Aug 3, 2026 | Kweli ThompsonEVP & President, Neuroscience | 6,923 | – | – | Form 4 | |
| Aug 3, 2026 | Michelle QuinnEVP, GC and Secretary | 6,346 | – | – | Form 4 | |
| Aug 3, 2026 | Thierry PietonEVP & Chief Financial Officer | 11.5K | – | – | Form 4 | |
| Aug 3, 2026 | Michael MarinaroEVP, Pres MedSurg and Americas | 11.0K | – | – | Form 4 | |
| Aug 3, 2026 | Michael MarinaroEVP, Pres MedSurg and Americas | 46.1K | – | – | Form 4 | |
| Aug 3, 2026 | Harry Skip KiilEVP & President Cardiovascular | 9,230 | – | – | Form 4 | |
| Aug 3, 2026 | Geoffrey MarthaChairman and CEO | 41.5K | – | – | Form 4 | |
| Jul 31, 2026 | Denise L. BlomquistChief Accounting Officer | 212 | $85.39 | $18.1K | Form 4 | |
| Jul 31, 2026 | Matthew R. WalterSVP, Chief HR Officer | 1,675 | $85.39 | $143.0K | Form 4 | |
| Jul 31, 2026 | Kweli ThompsonEVP & President, Neuroscience | 1,739 | $85.39 | $148.5K | Form 4 | |
| Jul 31, 2026 | Michael MarinaroEVP, Pres MedSurg and Americas | 3,356 | $85.39 | $286.6K | Form 4 | |
| Jul 31, 2026 | Harry Skip KiilEVP & President Cardiovascular | 3,074 | $85.39 | $262.5K | Form 4 | |
| Jul 31, 2026 | Geoffrey MarthaChairman and CEO | 15.8K | $85.39 | $1.4M | Form 4 | |
| Jul 28, 2026 | Michelle QuinnEVP, GC and Secretary | 2,069 | $86.88 | $179.8K | Form 4 | |
| Jul 8, 2026 | Matthew R. WalterSVP, Chief HR Officer | 10b5-1 | 3,102 | $83.15 | $257.9K | Form 4 |
| Jun 8, 2026 | Harry Skip KiilEVP & President Cardiovascular | 3,961 | $80.44 | $318.6K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 28, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by MDT's officers and directors from 2015 up to November 18, 2025, 11 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 6 more, back to 2015
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- The Vanguard Group0.00%Mar 27, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+447%
- D.E. ShawIn the quarter+391%
- Bridgewater (Dalio)In the quarter+89%
- Renaissance TechnologiesIn the quarter-72%
- AQR CapitalIn the quarter+103%
- Millennium Mgmt (Englander)In the quarter+94%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 5.37M | +447% | $420M | 0.24% |
| D.E. Shaw | 4.40M | +391% | $344M | 0.21% |
| Bridgewater (Dalio) | 482.5K | +89% | $38M | 0.15% |
| Renaissance Technologies | 887.8K | -72% | $77M | 0.10% |
| AQR Capital | 3.30M | +103% | $258M | 0.09% |
| Millennium Mgmt (Englander) | 918.5K | +94% | $72M | 0.05% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 10.9% of its shares outstanding were held short, +247.7% since the report before.
- Shares held short
- 139M
- 10.9%
- Since the report before39.97M on Sep 30, 2026
- +247.7%
- 2.9
- 47.50M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 34%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 7.53M
- Nov 15, 2023: Shares held short 8.68M
- Nov 30, 2023: Shares held short 8.73M
- Dec 15, 2023: Shares held short 8.33M
- Dec 29, 2023: Shares held short 8.89M
- Jan 12, 2024: Shares held short 11.39M
- Jan 31, 2024: Shares held short 10.87M
- Feb 15, 2024: Shares held short 9.81M
- Feb 29, 2024: Shares held short 8.45M
- Mar 15, 2024: Shares held short 11.53M
- Mar 28, 2024: Shares held short 12.43M
- Apr 15, 2024: Shares held short 12.39M
- Apr 30, 2024: Shares held short 14.03M
- May 15, 2024: Shares held short 15.33M
- May 31, 2024: Shares held short 13.32M
- Jun 14, 2024: Shares held short 16.36M
- Jun 28, 2024: Shares held short 15.22M
- Jul 15, 2024: Shares held short 13.68M
- Jul 31, 2024: Shares held short 13.42M
- Aug 15, 2024: Shares held short 14.84M
- Aug 30, 2024: Shares held short 16.50M
- Sep 13, 2024: Shares held short 12.70M
- Sep 30, 2024: Shares held short 10.67M
- Oct 15, 2024: Shares held short 10.77M
- Oct 31, 2024: Shares held short 10.18M
- Nov 15, 2024: Shares held short 11.89M
- Nov 29, 2024: Shares held short 10.01M
- Dec 13, 2024: Shares held short 11.32M
- Dec 31, 2024: Shares held short 9.81M
- Jan 15, 2025: Shares held short 12.85M
- Jan 31, 2025: Shares held short 14.00M
- Feb 14, 2025: Shares held short 13.24M
- Feb 28, 2025: Shares held short 13.49M
- Mar 14, 2025: Shares held short 12.83M
- Mar 31, 2025: Shares held short 10.84M
- Apr 15, 2025: Shares held short 12.66M
- Apr 30, 2025: Shares held short 12.24M
- May 15, 2025: Shares held short 13.63M
- May 30, 2025: Shares held short 7.88M
- Jun 13, 2025: Shares held short 8.47M
- Jun 30, 2025: Shares held short 12.06M
- Jul 15, 2025: Shares held short 13.07M
- Jul 31, 2025: Shares held short 11.60M
- Aug 15, 2025: Shares held short 14.09M
- Aug 29, 2025: Shares held short 13.23M
- Sep 15, 2025: Shares held short 12.79M
- Sep 30, 2025: Shares held short 10.66M
- Oct 15, 2025: Shares held short 14.95M
- Oct 31, 2025: Shares held short 14.43M
- Nov 14, 2025: Shares held short 13.53M
- Nov 28, 2025: Shares held short 18.97M
- Dec 15, 2025: Shares held short 15.13M
- Dec 31, 2025: Shares held short 14.40M
- Jan 15, 2026: Shares held short 16.77M
- Jan 30, 2026: Shares held short 19.72M
- Feb 13, 2026: Shares held short 17.33M
- Feb 27, 2026: Shares held short 15.43M
- Mar 13, 2026: Shares held short 16.59M
- Mar 31, 2026: Shares held short 16.98M
- Apr 15, 2026: Shares held short 15.46M
- Apr 30, 2026: Shares held short 14.60M
- May 15, 2026: Shares held short 14.65M
- May 29, 2026: Shares held short 16.76M
- Jun 15, 2026: Shares held short 18.43M
- Jun 30, 2026: Shares held short 19.09M
- Jul 15, 2026: Shares held short 19.03M
- Jul 31, 2026: Shares held short 18.12M
- Aug 14, 2026: Shares held short 14.35M
- Aug 31, 2026: Shares held short 12.13M
- Sep 15, 2026: Shares held short 17.23M
- Sep 30, 2026: Shares held short 39.97M
- Oct 15, 2026: Shares held short 139M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading39.3% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 39.3% of the shares in the reported trades were short sales, against 48.8% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 39.3%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 48.8%
- Change
- -9.5 pts
- Short sales a dayon average, of 2.63M shares
- 1.03M
- More than atof 3,656 US-listed companies, same days
- 18%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 63.6%
- Oct 13, 2026: Short sales 46.6%
- Oct 14, 2026: Short sales 49.8%
- Oct 15, 2026: Short sales 41.7%
- Oct 16, 2026: Short sales 44.8%
- Oct 19, 2026: Short sales 41.6%
- Oct 20, 2026: Short sales 51.9%
- Oct 21, 2026: Short sales 53.8%
- Oct 22, 2026: Short sales 39.1%
- Oct 23, 2026: Short sales 42.2%
- Oct 26, 2026: Short sales 55.2%
- Oct 27, 2026: Short sales 37.2%
- Oct 28, 2026: Short sales 41.6%
- Oct 29, 2026: Short sales 39.9%
- Oct 30, 2026: Short sales 51.3%
- Nov 2, 2026: Short sales 52%
- Nov 3, 2026: Short sales 39.4%
- Nov 4, 2026: Short sales 38.1%
- Nov 5, 2026: Short sales 46%
- Nov 6, 2026: Short sales 30.8%
- Nov 9, 2026: Short sales 30.6%
- Nov 10, 2026: Short sales 39.2%
- Nov 11, 2026: Short sales 35.5%
- Nov 12, 2026: Short sales 38.3%
- Nov 13, 2026: Short sales 41.1%
- Nov 16, 2026: Short sales 34.2%
- Nov 17, 2026: Short sales 29.1%
- Nov 18, 2026: Short sales 32.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Geoffrey MarthaChairman and CEODirectly277.9K
- Michael MarinaroPresidentDirectly113.4K
- Brett A. WallEVP & Pres NeuroscienceDirectly82.2K
- Thierry PietonEVP & Chief Financial OfficerDirectly49.6K
- Harry Skip KiilEVP & President CardiovascularDirectly42.2K
- Matthew R. WalterSVP, Chief HR OfficerDirectly39.9K
- Kweli ThompsonEVP & President, NeuroscienceDirectly35.4K
- Michelle QuinnEVP, GC and SecretaryDirectly26.7K
- Denise L. BlomquistChief Accounting OfficerDirectly16.4K
- Kevin E LoftonDirectorDirectly9,977
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Geoffrey MarthaChairman and CEO | 277.9K | – | Oct 15, 2026 | Form 4 |
| Michael MarinaroPresident | 113.4K | – | Nov 2, 2026 | Form 4 |
| Brett A. WallEVP & Pres Neuroscience | 82.2K | – | May 26, 2026 | Form 4 |
| Thierry PietonEVP & Chief Financial Officer | 49.6K | – | Aug 3, 2026 | Form 4 |
| Harry Skip KiilEVP & President Cardiovascular | 42.2K | – | Sep 16, 2026 | Form 4 |
| Matthew R. WalterSVP, Chief HR Officer | 39.9K | – | Aug 3, 2026 | Form 4 |
| Kweli ThompsonEVP & President, Neuroscience | 35.4K | – | Aug 3, 2026 | Form 4 |
| Michelle QuinnEVP, GC and Secretary | 26.7K | – | Aug 3, 2026 | Form 4 |
| Denise L. BlomquistChief Accounting Officer | 16.4K | – | Sep 15, 2026 | Form 4 |
| Kevin E LoftonDirector | 9,977 | – | Oct 15, 2026 | Form 4 |
A lower bound: it counts only the 10 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Geoff MarthaChairman and Chief Executive OfficerWhat happenedAdoptedJul 16, 2026Shares50.0K
- Matthew WalterSenior Vice President, Human Resources, IT, and Global Communications & Corporate MarketingWhat happenedAdoptedFeb 27, 2026Shares3,102
- Michael MarinaroExecutive Vice PresidentWhat happenedAdoptedFeb 19, 2026Shares10.4K
- Brett WallExecutive Vice President and PresidentWhat happenedAdoptedOct 10, 2024Shares22.3K
- Brett WallExecutive Vice President and President Neuroscience PortfolioWhat happenedAdoptedSep 20, 2023Shares4,997
- Karen L. ParkhillExecutive Vice President and Chief Financial OfficerWhat happenedAdoptedJul 14, 2023Shares3,351
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Geoff MarthaChairman and Chief Executive Officer | AdoptedJul 16, 2026 | Nov 30, 2026 | 50.0K | 10-Q |
| Matthew WalterSenior Vice President, Human Resources, IT, and Global Communications & Corporate Marketing | AdoptedFeb 27, 2026 | Jul 10, 2026 | 3,102 | 10-K |
| Michael MarinaroExecutive Vice President | AdoptedFeb 19, 2026 | Dec 15, 2026 | 10.4K | 10-K |
| Brett WallExecutive Vice President and President | AdoptedOct 10, 2024 | Aug 1, 2025 | 22.3K | 10-Q |
| Brett WallExecutive Vice President and President Neuroscience Portfolio | AdoptedSep 20, 2023 | 93 days | 4,997 | 10-Q |
| Karen L. ParkhillExecutive Vice President and Chief Financial Officer | AdoptedJul 14, 2023 | – | 3,351 | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$23M
Actually paid: $22M
$7.3M
Actually paid: $7.2M
$74
Peers: $97
Revenue Growth
From the proxy statement (DEF 14A) of Aug 17, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jul 31, 202610-QAmount$226M
- Apr 24, 202610-KAmount$430M
- Jan 23, 202610-QAmount$85M
- Oct 24, 202510-QAmount$309M
- Jul 25, 202510-QAmount$120M
- Apr 25, 202510-KAmount$264M
- Jan 24, 202510-QAmount$164M
- Oct 25, 202410-QAmount$248M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jul 31, 202610-Q | 2.77M | $81.56 | $226M | $958M | 10-Q |
| Apr 24, 202610-K | 4.51M | $95.34 | $430M | $1.2B | 10-K |
| Jan 23, 202610-Q | 917.7K | $92.63 | $85M | $1.6B | 10-Q |
| Oct 24, 202510-Q | 3.30M | $93.54 | $309M | $1.7B | 10-Q |
| Jul 25, 202510-Q | 1.39M | $86.22 | $120M | $2.0B | 10-Q |
| Apr 25, 202510-K | 2.91M | $90.70 | $264M | $2.1B | 10-K |
| Jan 24, 202510-Q | 1.93M | $85.01 | $164M | $2.4B | 10-Q |
| Oct 25, 202410-Q | 2.88M | $86.26 | $248M | $2.6B | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 1 filing(s) not shown, as the table was not read or did not agree with the cash.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026Oct 19, 2026For93.7%
- 2025Oct 21, 2025For93.5%
- 2024Oct 21, 2024For92.9%
- 2023Oct 23, 2023For93.4%
- 2022Dec 13, 2022For93.3%
- 2021Dec 14, 2021For90.3%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026Oct 19, 2026 | 93.7% | 936M | 62.50M | 2.79M | 115M | 8-K |
| 2025Oct 21, 2025 | 93.5% | 925M | 64.82M | 1.62M | 118M | 8-K |
| 2024Oct 21, 2024 | 92.9% | 925M | 70.30M | 5.18M | 118M | 8-K |
| 2023Oct 23, 2023 | 93.4% | 968M | 68.91M | 4.57M | 123M | 8-K |
| 2022Dec 13, 2022 | 93.3% | 972M | 69.94M | 2.12M | 116M | 8-K |
| 2021Dec 14, 2021 | 90.3% | 939M | 101M | 3.56M | 106M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHIiShares U.S. Medical Devices ETFWeight in the fund4.40%
- FDLFirst Trust Morningstar Dividend Leaders Index FundWeight in the fund2.28%
- IYHiShares U.S. Healthcare ETFWeight in the fund1.80%
- SPHDInvesco S&P 500 High Dividend Low Volatility ETFWeight in the fund1.79%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund1.75%
- HDViShares Core High Dividend ETFWeight in the fund1.73%
- VHTVanguard Health Care Index FundWeight in the fund1.61%
- NOBLProShares S&P 500 Dividend Aristocrats ETFWeight in the fund1.56%
- IXJiShares Global Healthcare ETFWeight in the fund1.30%
- SDYState Street(R) SPDR(R) S&P(R) Dividend ETFWeight in the fund1.30%
60 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 2,182
- Q4 2025: Managers 2,317
- Q1 2026: Managers 2,251
- Q2 2026: Managers 2,136
Institutional investors by quarter
The fund managers holding MDT, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 2,136 managers held 1.11B shares, worth $87.9B. During the quarter 167 opened a position, 282 closed one, 840 added and 905 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+0.7%
- Vanguard Capital ManagementIn the quarter+0.6%
- State StreetIn the quarter+2.7%
- Vanguard Portfolio ManagementIn the quarter+1.8%
- Geode Capital ManagementIn the quarter+5.1%
- JPMorgan ChaseIn the quarter-45%
- First Eagle Investment ManagementIn the quarter+174%
- Bank of AmericaIn the quarter-18%
- Massachusetts Financial ServicesIn the quarter-7.3%
- Morgan StanleyIn the quarter-6.1%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 114M | +0.7% | $8.9B |
| Vanguard Capital Management | 83.82M | +0.6% | $6.6B |
| State Street | 63.40M | +2.7% | $5.0B |
| Vanguard Portfolio Management | 34.06M | +1.8% | $2.7B |
| Geode Capital Management | 30.19M | +5.1% | $2.4B |
| JPMorgan Chase | 27.78M | -45% | $2.2B |
| First Eagle Investment Management | 27.57M | +174% | $2.2B |
| Bank of America | 21.32M | -18% | $1.7B |
| Massachusetts Financial Services | 19.87M | -7.3% | $2.6B |
| Morgan Stanley | 19.44M | -6.1% | $1.5B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Medtronic's filings show?
Who buys and sells is one part of Medtronic's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have MDT's insiders bought or sold?
From May 28, 2026 to Nov 4, 2026 Medtronic's insiders bought 0 and sold $6.5M of shares on the market. 93% of the sales were under set 10b5-1 plans.
Which well-known managers hold MDT?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $420M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.